Expanding regulatory approvals, increasing biologics pipelines, and escalating expense in subsequent-era peptide modalities continue to produce 2025 a pivotal growth 12 months for the marketplace.Biggest concentration of peptide CDMOs; robust SPPS reactor capacity and immediate scale-up abil